Antiarrhythmogenic Effect of Reconstituted High-Density Lipoprotein Against Ischemia/Reperfusion in Rats

Journal of the American College of Cardiology

Volumn 51, Issue 16, 2008, Pages 1604-1612

  Imaizumi, Satoshi ^a   Miura, Shin ichiro ^a   Nakamura, Kazuto ^b   Kiya, Yoshihiro ^a   Uehara, Yoshinari ^a   Zhang, Bo ^a   Matsuo, Yoshino ^a   Urata, Hidenori ^c   Ideishi, Munehito ^a   Rye, Kerry Anne ^d   Sata, Masataka ^b   Saku, Keijiro ^a  

^a FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c Fukuoka University Chikushi Hospital   (Japan)

^d HEART RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 OLEOYL 1 PALMITOYLPHOSPHATIDYLCHOLINE; ABC TRANSPORTER A1; APOLIPOPROTEIN A1; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HIGH DENSITY LIPOPROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; RECOMBINANT PROTEIN; RECONSTITUTED HIGH DENSITY LIPOPROTEIN; SCAVENGER RECEPTOR BI; UNCLASSIFIED DRUG; WORTMANNIN;

AGAR GEL ELECTROPHORESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE MONITORING; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY DISEASE; DRUG EFFECT; DRUG INHIBITION; ELECTROCARDIOGRAM; ENDOTHELIUM CELL; HEART ARRHYTHMIA; HEART FUNCTION; HEART INFARCTION; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; IMMUNOHISTOCHEMISTRY; ISCHEMIA; LIPOPROTEIN BLOOD LEVEL; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REPERFUSION; REPERFUSION INJURY; SINUS RHYTHM; VASODILATATION;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; APOLIPOPROTEIN A-I; CHOLESTEROL, HDL; ENDOTHELIUM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; MALE; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION; NITRIC OXIDE; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION; TACHYCARDIA, VENTRICULAR;

EID: 41949094290     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2007.12.040     Document Type: Article

References (39)

1. Linsel-Nitschke P., and Tall A.R. HDL as a target in the treatment of atherosclerotic cardiovascular disease. Nat Rev Drug Discov 4 (2005) 193-205
2. Wannamethee G., Shaper A.G., Macfarlane P.W., and Walker M. Risk factors for sudden cardiac death in middle-aged British men. Circulation 91 (1995) 1749-1756
3. Burke A.P., Farb A., Malcom G.T., Liang Y.H., Smialek J., and Virmani R. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med 336 (1997) 1276-1282
4. Liu Y.B., Wu C.C., Lee C.M., et al. Dyslipidemia is associated with ventricular tachyarrhythmia in patients with acute ST-segment elevation myocardial infarction. J Formos Med Assoc 105 (2006) 17-24
5. Mochlzuki S., Okumura M., Tanaka F., et al. Ischemia-reperfusion arrhythmias and lipids: effect of human high- and low-density lipoproteins on reperfusion arrhythmias. Cardiovasc Drugs Ther 5 (1991) 269-276
6. Kuvin J.T., Alsheikh-Ali A.A., and Karas R.H. High-density lipoprotein cholesterol-raising strategies. J Cardiovasc Pharmacol 47 (2006) 196-204
7. Calabresi L., Rossoni G., Gomaraschi M., Sisto F., Berti F., and Franceschini G. High-density lipoproteins protect isolated rat hearts from ischemia-reperfusion injury by reducing cardiac tumor necrosis factor-alpha content and enhancing prostaglandin release. Circ Res 92 (2003) 330-337
8. Vegh A., Komori S., Szekeres L., and Parratt J.R. Antiarrhythmic effects of preconditioning in anaesthetised dogs and rats. Cardiovasc Res 26 (1992) 487-495
9. Yahiro E., Ideishi M., Wang L.X., et al. Reperfusion-induced arrhythmias are suppressed by inhibition of the angiotensin II type 1 receptor. Cardiology 99 (2003) 61-67
10. Jalowy A., Schulz R., and Heusch G. AT1 receptor blockade in experimental myocardial ischemia/reperfusion. J Am Soc Nephrol 10 Suppl 11 (1999) S129-S136
11. Rye K.A., Garrety K.H., and Barter P.J. Changes in the size of reconstituted high density lipoproteins during incubation with cholesteryl ester transfer protein: the role of apolipoproteins. J Lipid Res 33 (1992) 215-224
12. Walker M.J., Curtis M.J., Hearse D.J., et al. The Lambeth Conventions: guidelines for the study of arrhythmias in ischaemia infarction, and reperfusion. Cardiovasc Res 22 (1988) 447-455
13. Zhang B., Matsunaga A., Saku K., Nakano S., and Yamada T. Associations among plasma lipoprotein subfractions as characterized by analytical capillary isotachophoresis, apolipoprotein E phenotype, Alzheimer disease, and mild cognitive impairment. Arterioscler Thromb Vasc Biol 24 (2004) e144-e146
14. Kingsley D.M., and Krieger M. Receptor-mediated endocytosis of low density lipoprotein: somatic cell mutants define multiple genes required for expression of surface-receptor activity. Proc Natl Acad Sci U S A 81 (1984) 5454-5458
15. Miura S., Matsuo Y., and Saku K. Transactivation of KDR/Flk-1 by the B2 receptor induces tube formation in human coronary endothelial cells. Hypertension 41 (2003) 1118-1123
16. Bottcher A., Schlosser J., Kronenberg F., et al. Preparative free-solution isotachophoresis for separation of human plasma lipoproteins: apolipoprotein and lipid composition of HDL subfractions. J Lipid Res 41 (2000) 905-915
17. Schmitz G., Mollers C., and Richter V. Analytical capillary isotachophoresis of human serum lipoproteins. Electrophoresis 18 (1997) 1807-1813
18. Nofer J.R., van der Giet M., Tolle M., et al. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J Clin Invest 113 (2004) 569-581
19. Zweier J.L., Wang P., Samouilov A., and Kuppusamy P. Enzyme-independent formation of nitric oxide in biological tissues. Nat Med 1 (1995) 804-809
20. Kim-Shapiro D.B., Schechter A.N., and Gladwin M.T. Unraveling the reactions of nitric oxide, nitrite, and hemoglobin in physiology and therapeutics. Arterioscler Thromb Vasc Biol 26 (2006) 697-705
21. Jugdutt B.I. Nitric oxide and cardioprotection during ischemia-reperfusion. Heart Fail Rev 7 (2002) 391-405
22. Stangl V., Baumann G., Stangl K., and Felix S.B. Negative inotropic mediators released from the heart after myocardial ischaemia-reperfusion. Cardiovasc Res 53 (2002) 12-30
23. Zhang B., Miura S., Fan P., et al. ApoA-I/phosphatidylcholine discs remodels fast-migrating HDL into slow-migrating HDL as characterized by capillary isotachophoresis. Atherosclerosis 188 (2006) 95-101
24. Nanjee M.N., Doran J.E., Lerch P.G., and Miller N.E. Acute effects of intravenous infusion of ApoA1/phosphatidylcholine discs on plasma lipoproteins in humans. Arterioscler Thromb Vasc Biol 19 (1999) 979-989
25. Rye K.A., and Barter P.J. Formation and metabolism of prebeta-migrating, lipid-poor apolipoprotein A-I. Arterioscler Thromb Vasc Biol 24 (2004) 421-428
26. Mineo C., Yuhanna I.S., Quon M.J., and Shaul P.W. High density lipoprotein-induced endothelial nitric-oxide synthase activation is mediated by Akt and MAP kinases. J Biol Chem 278 (2003) 9142-9149
27. Haidar B., Denis M., Marcil M., Krimbou L., and Genest Jr. J. Apolipoprotein A-I activates cellular cAMP signaling through the ABCA1 transporter. J Biol Chem 279 (2004) 9963-9969
28. Rader D.J. Molecular regulation of HDL metabolism and function: implications for novel therapies. J Clin Invest 116 (2006) 3090-3100
29. Matsuo Y., Miura S.I., Kawamura A., Uehara Y., Rye K.A., and Saku K. Newly developed reconstituted high-density lipoprotein containing sphingosine-1-phosphate induces endothelial tube formation. Atherosclerosis 194 (2007) 159-168
30. Moens A.L., Claeys M.J., Timmermans J.P., and Vrints C.J. Myocardial ischemia/reperfusion-injury, a clinical view on a complex pathophysiological process. Int J Cardiol 100 (2005) 179-190
31. Ravens U., and Himmel H.M. Drugs preventing Na+ and Ca2+ overload. Pharmacol Res 39 (1999) 167-174
32. Kubota I., Han X., Opel D.J., et al. Increased susceptibility to development of triggered activity in myocytes from mice with targeted disruption of endothelial nitric oxide synthase. J Mol Cell Cardiol 32 (2000) 1239-1248
33. Russwurm M., and Koesling D. NO activation of guanylyl cyclase. Embo J 23 (2004) 4443-4450
34. Pabla R., Bland-Ward P., Moore P.K., and Curtis M.J. An endogenous protectant effect of cardiac cyclic GMP against reperfusion-induced ventricular fibrillation in the rat heart. Br J Pharmacol 116 (1995) 2923-2930
35. Mery P.F., Lohmann S.M., Walter U., and Fischmeister R. Ca2+ current is regulated by cyclic GMP-dependent protein kinase in mammalian cardiac myocytes. Proc Natl Acad Sci U S A 88 (1991) 1197-1201
36. Luscher T.F. Endothelium-derived nitric oxide: the endogenous nitrovasodilator in the human cardiovascular system. Eur Heart J 12 Suppl E (1991) 2-11
37. Rossoni G., Manfredi B., De Gennaro Colonna V., et al. Nitric oxide and prostacyclin pathways: an integrated mechanism that limits myocardial infarction progression in anaesthetized rats. Pharmacol Res 53 (2006) 359-366
38. Kiya Y., Miura S., Imaizumi S., et al. Reconstituted high-density lipoprotein prevents pathological remodeling after myocardial infarction. Circ J 69 (2005) 646 (abstr)
39. Kiyatkin E.A., and Brown P.L. Brain and body temperature homeostasis during sodium pentobarbital anesthesia with and without body warming in rats. Physiol Behav 84 (2005) 563-570